亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Dual Tyrosyl-DNA Phosphodiesterase/Topoisomerase Inibitors

总结: Purdue University researchers have developed a series of novel, low molecular-weight compounds that can act as dual inhibitors of both TOP1 and TDP1. A dual inhibitor of this type would offer significant advantages over individual TOP1 and TDP1inhibitors alone such as simplification of delivery and bioavailability. In lab tests, the dual inhibitor is an equally potent TOP1 inhibitor as the commercially available camptothecin. These molecules are thought to function by stalling the DNA synthesis phase of the cell cycle, thereby inducing apoptosis, and effectively killing the cell. This drug could work in combination with other chemotherapies to effectively eliminate highly proliferative cell growth in the body.

技术优势: First dual inhibitor of TOP1 and TDP1Shown to be as cytotoxic to TOP1 as camptothecinA potentially more potent chemotherapy agent

*Background: Topoisomerase 1 (TOP1) is an enzyme involved in the replication of DNA. Molecules displaying TOP1 inhibitory function have found clinical applications as well as the frequent subject of research. Another enzyme functioning alongside TOP1 is tyrosyl-DNA phosphodiesterase 1 (TDP1), which repairs DNA lesions. Observations of this enzyme suggest mediating its activity could potentiate the cytotoxic effect of TOP1 inhibitors. TDP1 inhibitory activity has been seen to a limited extent in a handful of compounds, though their potencies, specificities, and pharmacokinetic properties leave much to be desired.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipMark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology

欲了解更多信息，请点击这里